Synthetic Oligonucleotides are set for rapid expansion in healthcare, food production, and data storage. The technology, vital in both existing and new markets, promises vast growth potential often ...

As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...

The use of oligonucleotides as therapeutic agents is of great interest, particularly when it comes to siRNA and antisense oligonucleotides. However, the difficulty of targeting the right organ and ...

This study addresses endosomal escape in oligonucleotide therapies and how engineered peptides can enhance intracellular drug delivery efficiency.

New York, USA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | ...

DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis Market: Forecast by Oligo Length, Application, Category, Type, Product, and Region, with Executive and Consultant Guides" report has been added ...

RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively ...

Epigenetic modifications such as DNA methylation play a key role in regulating gene expression. Emerging evidence suggests ...

Oligonucleotide therapeutics, which can modulate gene expression by a variety of mechanisms, have the potential to treat numerous diseases. Although several oligonucleotide-based drugs have recently ...

Antisense oligonucleotide (ASO) therapy has the potential to ameliorate many neurodegenerative diseases at the genetic level to suppress the production of harmful proteins or non-coding RNAs.

GSK has added another oligonucleotide to its pipeline, with potentially plenty more to follow courtesy of a $170 million upfront collaboration with Wave Life Sciences. As part of the deal, GSK will ...